Otsuka

Scientist in lab

(Photo credit: Getty Images/Westend61)

By  Laura Lovett 02:19 pm March 31, 2021
Over the last year, digital has transformed the caregiver experience, but pharma has also been undergoing a metamorphosis in order to reach patients. During the pandemic, life science companies were pushed to reconfigure their care in order to meet the needs of some of the most at-risk patients. MobiHealthNews sat down with the leader of pharma giant Otsuka's Global Clinical Development on...
Digital research
By  Laura Lovett 03:07 pm February 24, 2021
All around the world the coronavirus pandemic has led to an uptick in digital healthcare delivery models. While telemedicine is often touted as the poster child of digital success in 2020, digital therapeutics (DTx) also emerged as a player on the global stage. "What we are seeing is digital therapeutics, while they won’t directly treat COVID, they are really an integral component of this...
By  Dave Muoio 09:00 am February 24, 2021
Otsuka Pharmaceutical and Click Therapeutics have announced the launch of a new, fully remote clinical trial being conducted on Verily's Project Baseline platform. Called the Mirai study, it will be measuring a digital therapeutics intervention's effectiveness in reducing symptoms of depression among adults who have a major depressive disorder (MDD) diagnosis and are on antidepressant monotherapy...
By  Dave Muoio 03:23 pm August 20, 2020
Picking through the scraps. Following the bankruptcy of 'digital pill' maker Proteus Digital Health, business partner and stakeholder Otsuka Pharmaceutical has been approved to purchase the digital health company's assets by a federal bankruptcy court judge, STAT reports. Otsuka's bid was challenged by Novartis, two former Proteus executives and other investors, who argued that the agreed upon $...
By  Dave Muoio 02:51 pm June 16, 2020
Proteus Digital Health, maker of an ingestible sensor for tracking medication adherence, filed for Chapter 11 bankruptcy protection yesterday. The news comes months after word that the company had furloughed much of its staff, reassessed its high-profile partnership with Otsuka Pharmaceutical and shifted away from its primary focus area of mental disorder treatment. The "smart pill" maker...
By  Dave Muoio 05:01 pm December 13, 2019
It has been a tumultuous week in the realm of digital health partnerships. It started with word of Proteus Digital Health’s floundering business and failed investment round, which reports say was partially driven by cooling relations between the digital pill maker and its longtime patron Otsuka Pharmaceuticals. A few days later, Sanofi announced a company-wide strategy shift that found Onduo, its...
By  Dave Muoio 01:03 pm December 9, 2019
Proteus Digital Health, maker of an ingestible sensor system for treatment adherence monitoring, was forced to furlough many of its employees last month after a $100 million funding round didn’t close as expected, according to a weekend report from CNBC. These employees were brought back after about two weeks after Proteus was able to secure $5 million in emergency funding, according to the...
By  Dave Muoio 10:03 am May 21, 2019
This morning Verily announced a series of new strategic partnerships with four global pharmaceutical companies that will bring low-burden digital data collection and analysis tools to clinical research projects. Alongside Novartis, Otsuka, Pfizer and Sanofi, the Alphabet subsidiary will employ its Project Baseline platform to increase the number and diversity of study populations by making it...
By  Laura Lovett 12:16 pm January 3, 2019
This morning Otsuka America, a subsidiary of the Japanese pharma company, announced that it is teaming up with Click Therapeutics, maker of software as a prescription medical treatment, to create a new digital therapeutic to treat major depressive disorder (MDD).  The goal of the partnership is to develop a software app that will employ cognitive therapy principles and can be used either with or...
By  Jonah Comstock 05:44 am November 7, 2018
By and large, Q3 2018 was a slow and steady quarter for pharma moves in digital health, at least in terms of publicly disclosed operations. At events during the quarter, the likes of Johnson & Johnson, AstraZeneca, Novartis and Sanofi discussed digital therapeutics and expressed a healthy mixture of skepticism and enthusiasm for the space. “These technologies have a tremendous opportunity to...